Lipolytic inhibitor G0S2 modulates glioma stem-like cell radiation response

Yinfang Wang¹, Yanli Hou¹,², Weiwei Zhang¹, Angel A. Alvarez³, Yongrui Bai², Bo Hu³, Shi-Yuan Cheng³, Kun Yang⁴*, Yanxin Li⁵* and Haizhong Feng¹*

Abstract

Background: Ionizing radiation (IR) therapy is the standard first-line treatment for newly diagnosed patients with glioblastoma (GBM), the most common and malignant primary brain tumor. However, the effects of IR are limited due to the aberrant radioresistance of GBM.

Methods: Transcriptome analysis was performed using RNA-seq in radioresistant patient-derived glioma stem-like cells (GSCs). Survival of glioma patient and mice bearing-brain tumors was analyzed by Kaplan–Meier survival analysis. Lipid droplet and γ-H2AX foci-positive cells were evaluated using immunofluorescence staining.

Results: Lipolytic inhibitor G0/G1 switch gene 2 (G0S2) is upregulated in radioresistant GSCs and elevated in clinical GBM. GBM patients with high G0S2 expression had significantly shorter overall survival compared with those with low expression of G0S2. Using genetic approaches targeting G0S2 in glioma cells and GSCs, we found that knockdown of G0S2 promoted lipid droplet turnover, inhibited GSC radioresistance, and extended survival of xenograft tumor mice with or without IR. In contrast, overexpression of G0S2 promoted glioma cell radiation resistance. Mechanistically, high expression of G0S2 reduced lipid droplet turnover and thereby attenuated E3 ligase RNF168-mediated 53BP1 ubiquitination through activated the mechanistic target of rapamycin (mTOR)-ribosomal S6 kinase (S6K) signaling and increased 53BP1 protein stability in response to IR, leading to enhanced DNA repair and glioma radioresistance.

Conclusions: Our findings uncover a new function for lipolytic inhibitor G0S2 as an important regulator for GSC radioresistance, suggesting G0S2 as a potential therapeutic target for treating gliomas.

Keywords: G0/G1 switch gene 2 (G0S2), Glioma stem cell (GSCs), 53BP1, Radioresistance

Introduction

Glioblastoma (GBM), a WHO grade IV brain tumor is the most common and malignant primary cancer of the central nervous system with a grim median survival of 14.6 months upon diagnosis [1]. Radiotherapy is the standard first line treatment for newly diagnosed patients with gliomas, but its effectiveness is limited given the tumor’s intrinsic resistance and propensity for recurrence [2, 3]. Although possible mechanisms have been attributed to GBM resistance to radiation treatments [4–6], the molecular mechanisms regulating radiation resistance of GBM are still unclear.

G0/G1 switch gene 2 (G0S2) was initially identified in lymphocytes through pharmaceutical stimulation of the G0 to G1 cell cycle transition [7, 8]. G0S2, a small 12 kDa protein, localizes to the mitochondria [9, 10], endoplasmic reticulum [11], and lipid droplets within the adipocytes [12]. G0S2 has been shown to play various important roles in cellular functions such as cell proliferation [13], apoptosis [10], and oxidative phosphorylation [9] in humans and mice. G0S2 is demonstrated to function as a lipolytic inhibitor in lipid metabolism to regulate lipid droplet turnover [12], and lipid droplets were
identified as a signature of GBM and inversely correlated with GBM patient survival [14]. Accumulated data have indicated that GOS2 is also involved in cancer [10, 15–17], including glioma [18]. However, the function of G0S2 in cancers is still largely unknown.

Here, by analyzing gene expression profiles in glioma stem cells (GSCs) treated with fractionated radiation, we found that G0S2 is significantly upregulated in radioresistant GSCs. We firstly examined G0S2 expression in glioma cells and clinical specimens. We then assessed the role of G0S2 in radiation response in glioma stem-like cells (GSCs) and glioma cell lines. Finally, we determined the mechanism by which G0S2 enhances radioresistance in gliomas.

Materials and methods

Cell lines
Glioma U87, LN229, T98G, U251 and LN444 cells were from ATCC (Manassas, VA, USA). Patient-derived glioma stem cell (GSC) lines, GSC 84, GSC 157, GSC 1123 and GSC 83 were from Dr. Ichiro Nakano [19]. GSC cells were maintained in DMEM/F12 supplemented with B27 (1:50), heparin (5 mg/ml), basic FGF (20 ng/ml), and EGF (20 ng/ml), and glioma cells were cultured in 10% FBS/DMEM as we previously described [19, 20].

Antibodies and reagents
The following antibodies were used in this study: an anti-G0S2 (dilution 1:200; Proteintech, IL, USA); an anti-phospho-Histone H2A.X (Ser139) (dilution 1:1000; EMD Millipore, Billerica, MA, USA); anti-53BP1 (dilution 1:500), anti-RNF168 (dilution 1:500), anti-CXCL5 (dilution 1:1000) and anti-Rad51 (dilution 1:1000)(Abcam, Cambridge, MA, USA). The secondary antibodies were from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Cell culture media and other reagents were from Invitrogen (Carlsbad, CA, USA), Sigma-Aldrich (St. Louis, MO, USA) or Peprotech (Rocky Hill, NJ, USA).

Patient samples
Four fresh samples of human GBM samples and paired normal brain (peritumoral) tissues were obtained from Renji Hospital, Shanghai, China.

Plasmids
G0S2 and RNF168 cDNAs were amplified by RT-PCR from normal human brain tissues and sequenced. The cDNAs were then subcloned into a lentivirus LeGO-iG vector. shRNAs for G0S2 and 53BP1 were purchased from Thermo Fisher Scientific (Waltham, MA, USA). pMT107-His-Ub was described in our previous report [20].

Cell transfections
Cell transfections were performed as we previously described [20].

RNA-Seq and differentially expressed gene analysis
Total RNA was extracted and purified using the Qiagen RNeasy Mini kit (Valencia, CA, USA) according to the manufacturer’s instructions. The quality of RNA was assessed by bioanalyzer before sequencing. Libraries for poly(A)+ RNA were prepared according to the Illumina protocol. Libraries were sequenced on Illumina HI-SEQ 2500 platforms. The criteria of Differentially Expressed Genes detection in this study are false discovery rate (FDR) < 0.01 and a fold change > 2. Gene Expression Omnibus (GEO) accession code: GSE79772.

Materials and methods

Western blotting assay
Western blotting assay was performed as we previously described [20]. Briefly, cells were lysed, and then the lysates were centrifuged. Protein concentrations were determined with a BCA protein assay kit. Equal amounts of cell lysates (a total of 30 μg of protein) were resolved in 2X SDS lysis buffer and analyzed.

Cell apoptosis assay
Cell apoptosis assay was performed using BD Annexin V: FITC Apoptosis Detection Kit (BD Biosciences, San Jose, CA, USA), according to the manufacturer’s instructions. Cells (5 x 10⁵) were washed in PBS and centrifuged at 200 x g for 5 min. The supernatant was aspirated. The cell pellet was incubated with annexin-V-FITC (at 1 mg/ml in Hepes buffer with 1.8 mM CaCl₂) for 5–10 min at room temperature, and added 1 ml Hepes containing 10 mg/ml propidium iodide. Cells were analysed immediately by flow cytometry.

RNA extraction and quantitative real-time PCR analysis
Total RNA was extracted from indicated cells using Trizol (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s instructions. Quantitative Real-Time PCR was performed in triplicate using the QuantiTect SYBR Green PCR Kit (Qiagen, Valencia, CA, USA) on a Rotorgene 6000 series PCR machine (Corbett Research, Valencia, CA, USA). All mRNA quantification data were normalized to ACTB, which was used as an internal control. The following G0S2 primer sets were used: 5′-GGCCCGTATGGAGACTGTGTG-3′ and 5′-CTTGCTTCTGGAGACCTGTG-3′.

BODIPY 493/503 staining of neutral lipid droplets
GSCs were incubated under normal growth conditions with 100 μM of oleic acid (OA) (Sigma-Aldrich, catalog number: O3008) complexed to albumin at a molar ratio of 8:1 for 16 h, and then incubate on BODIPY staining.
solution in the dark for 15 min at 37 °C according to the manufacturer’s instructions.

**Immunofluorescent staining and confocal microscopy**

Cells grown on coverslips were permeabilized with 0.3% Triton X-100-PBS for 15 min and blocked with 3% BSA for 60 min. After overnight incubation of primary antibodies at 4 °C, the slides were incubated with Alexa Fluor-labeled secondary antibodies, and then were further stained with Hoechst 33258 for 10 min and evaluated with a LSM710 confocal microscope (Zeiss, Germany).

**Tumorigenesis studies**

Athymic (Ncr nu/nu) female mice at an age of 6–8 weeks (SLAC, Shanghai, China) were used. Mice were randomly divided into 5–6 per group. Four thousand GSCs or 1 × 10⁶ human glioma cells were stereotactically implanted into the brain of the animals as we previously described [20, 21]. Mice were euthanized when neuro-pathological symptoms developed.

**Radiation treatment**

Cells or mice were irradiated at indicated doses with an X-RAD 160 irradiation system (Precision X-Ray, Inc., Kentwood, MI, USA). A radiation shield was used to protect animal body.

** Colony formation assay**

Clonogenic survival assay was performed as previously described [22, 23]. Briefly, approximately 5000 cells after IR were seeded in a 0.5% Noble Agar top layer with a bottom layer of 0.8% Noble Agar in each of the triplicate wells of a 24-well plate. TMZ was added into the top layer. Medium was added after plating and changed every 3 days thereafter. Colonies were scored after 2–4 weeks using Olympus SZX12 stereomicroscope.

**Statistical analysis**

Statistical analyses were performed in a GraphPad Prism version 5.0 for Windows (GraphPad Software Inc., San Diego, CA, USA). Survival analysis was carried out by Kaplan-Meier analysis and was compared with the log-rank tests. Comparison of treatments was analyzed using One-way ANOVA with Newman-Keuls post-test or a paired two-way Student’s t test as we previously described [21]. P values less than 0.05 were considered significant.

**Results**

**G0S2 is upregulated in radioresistant glioma stem cells**

To identify novel mediators of radiation resistance in GBM, we treated a patient-derived glioma stem cell (GSC) line (GSC 1123-C) with repeated fractionated radiation to establish a radioresistant GSC line (GSC 1123-R). As shown in Additional file 1: Figure S1A, we subjected GSC 1123-C to four rounds of fractionated radiation of 6 Gy every 4 days (total 24 Gy), generating GSCs with greater radiation resistance GSC 1123-R, a pool of cells. GSC 1123-R cells at passage 10 or less were further analyzed. As shown in Additional file 1: Figure S1B and S1C, annexin V staining for apoptotic cells revealed that only 6.1% ± 0.5% of GSC 1123-R cells underwent apoptosis during the 48 h after a single-6 Gy dose irradiation, compared with a 11.2% ± 0.4% of GSC 1123-C cells. Clonogenic assays showed that the surviving fraction of cells receiving single 4- or 6-Gy IR was significantly higher for GSC 1123-R cells than for GSC 1123-C cells (Additional file 1: Figure S1D and S1E). This observation demonstrates that GSC 1123-R cells are more resistant to radiation when compared with GSC 1123-C cells, and were stable in radiation resistance.

Next, we performed transcriptome analysis of GSC 1123-R and GSC 1123-C using RNA-seq. Differential gene expression analysis identified 32 genes that were differentially expressed in GSC 1123-R compared with GSC 1123-C (false discovery rate < 0.01, and a fold change > 2), including ALDH1A3 (Aldehyde dehydrogenase 1A3) and G0S2 (Fig. 1a). To validate these RNA-seq results, we performed quantitative real-time PCR (qRT-PCR) analysis of ALDH1A3 and G0S2 expression. The data showed an agreement in the expression levels of these genes between the RNA-seq and qRT-PCR analyses (Fig. 1b). We further confirmed that protein expression of G0S2 was higher in GSC 1123-R cells compared with GSC 1123-C cells (Fig. 1c). This result suggests that G0S2 could regulate glioma radioresistance.

We then assessed expression of G0S2 in glioma cells and clinical specimens of patients. We downloaded the GSE67089 dataset [19] and examined G0S2 mRNA expression in proneural (PN), mesenchymal (MES) subtyped GSCs, astrocytes, 16WF neural stem cells (NSCs) and five established glioma cell lines. As shown in Fig. 1d, G0S2 was expressed at the highest levels in MES GSCs compared with all other cells. G0S2 was also co-expressed with MES-associated genes, CD44 and ALDH1A3 in MES GSCs [19]. The expression level of G0S2 protein was also the highest in MES GSCs, GSC 1123 and GSC 83 (Fig. 1e) when compared to other cell lines that were analyzed. In clinical tumor samples, compared to paired normal brain tissues, G0S2 was found highly expressed in three of four clinical GBM tissue samples (Fig. 1f). To support our findings, we downloaded GSE7696 [24] and GDS1962 [25] datasets and examined expression level of G0S2 mRNA in GBM, low grade (WHO grade II and III) and normal brain tissue controls included in these datasets. As shown in Fig. 1g and h, compared with normal brain tissues and low grade gliomas, the expression level of G0S2 mRNA was
Fig. 1 G0S2 is upregulated in radioresistant glioma stem cells (GSCs).  

**a** Heatmap of mRNA-Seq analysis of differentially expressed genes (2-fold change and FDR < 0.01) between GSC 1123-C and GSC 1123-R cells.  

**b** Quantitative RT-PCR (QRT-PCR) analysis of ALDH1A3 and G0S2 mRNA expression in GSC 1123-C and GSC 1123-R cells. ACTB (encoding β-actin) was used as a control. Error bars, SD. *, p < 0.05.  

**c** Western blotting (WB) assays of ALDH1A3 and G0S2 expression in GSC 1123-C and GSC 1123-R cells. β-actin was used as a control. 

**d** Expression level of G0S2 mRNA in proneural (PN) and mesenchymal (MES) GSCs, neural progenitors (NSC 16WF), normal astrocytes and glioma cell lines from the GSE67089 dataset [19].  

**e** WB analysis of G0S2 expression in GSC and glioma cells. β-actin was used as a control.  

**f** WB analysis of G0S2 expression in four paired clinical GBM samples and normal brain tissues.  

**g** Expression level of G0S2 mRNA is significantly higher in GBM compared with normal brains. Expression data of G0S2 mRNA were downloaded from the GSE7696 dataset [24] and analyzed.  

**h** Expression level of G0S2 mRNA is correlated with glioma progression. Expression data of G0S2 mRNA were downloaded from GSE1962 dataset [25] and analyzed.  

**i** GSE4271 dataset [44] and analyzed.  

**j** Kaplan–Meier analysis of patients with high G0S2 mRNA-expressing glioma tumors versus low G0S2 mRNA-expressing tumors in GBM from the GSE13041 dataset. Statistical analysis was performed by log-rank test in a GraphPad Prism version 5.0 for Windows. Median survival (in months): low, 12.83; high, 10.58. Black bars, censored data. Data in (B, C, E and F) represent two independent experiments with similar results.
significantly elevated in GBM, while no significant differences were measured between normal and low grade gliomas. We also found that the expression level of G0S2 was markedly higher in recurrent GBM than paired newly diagnosed GBM (Fig. 1i).

Last, we examined the relationship of G0S2 expression and glioma patient survival by Kaplan–Meier survival analysis using the GSE13041 dataset [26]. Segregating patients in the GSE13041 dataset by G0S2 expression revealed a statistically significant worse prognosis for GBM patients with high G0S2 (>1.2 x median level) compared with those with low (<1.2 x median level) (Fig. 1). The median patient survival times of these patients were 10.6 and 12.8 months, respectively (p < 0.05). This result supports that G0S2 is upregulated in radiation resistant GSCs and may be involved in glioma progression.

G0S2 mediates lipid droplet turnover and glioma irradiation response
Since G0S2 is upregulated in radioresistant GSCs, we determined whether G0S2 is involved in glioma radiation resistance. We used lentivirus-mediated short hairpin RNAs (shRNAs) targeting G0S2 or a non-silencing control to deplete G0S2 in two patient-derived GSCs, GSC 1123 and GSC 83 (Fig. 2a). We treated GSC 1123/shG0S2, GSC 1123/shC, GSC 83/shG0S2, and GSC 83/shC cells with fractionated irradiation (IR) at clinically relevant doses. As shown in Fig. 2b, knockdown of G0S2 markedly sensitized GSC 1123 and GSC 83 GSC cells to IR treatments as determined using clonogenic assays.

As G0S2 is a lipolytic inhibitor of adipose triglyceride lipase (ATGL) and regulates lipid droplet turnover [12], we examined whether G0S2-mediated radioresistance is related with G0S2 lipolytic inhibitor activity. GSC 1123 and GSC 83 cells transduced with or without G0S2 shRNAs were incubated in normal medium with oleic acid (OA) for 16 h to promote lipid droplet turnover (Fig. 2c). Using BODIPY 493/503, a nonpolar probe selective for neural lipids such as TAG [27], we identified that lipid droplets in GSC 1123/shG0S2 and GSC 83/shG0S2 cells were significantly smaller and lower numerous compared to those in the control cells, respectively (Fig. 2c and d). We then assessed cell apoptosis using fluorescence activated cell sort (FACS). As shown in Fig. 2e and f, knockdown of G0S2 promoted cell apoptosis in GSC 1123 cells, and IR treatment further increased cell apoptosis, whereas OA pre-treatment inhibited IR-induced cell apoptosis in GSC 1123/shG0S2 cells. These results support that G0S2-enhanced radioresistance is related with G0S2-regulated lipid droplet stability.

We further assessed the effect of G0S2 depletion on tumor growth in the brain of mice in response to IR treatment. Ten days after intracranial implantation of GSCs, half of the mice of each group (GSC 1123/shC or GSC 1123/shG0S2) received local IR to the brain for 4 consecutive days at 2.5 Gy/day. Kaplan-Meier survival assay showed that in mice with GSC 1123/shC tumors but without IR treatments, median survival was 17.0 days post-implantation. In contrast, the animals with shG0S2 tumors survived 21.5 days (p < 0.01) (Fig. 2g). IR treatment had a modest effect on control animal survival, with median survival times of 17.0 and 23.0 days (p < 0.01), respectively. However, the combination of shG0S2 and IR led to the most significant extension of animal survival with a median survival time of 33.0 days when compared to a median survival time of 23.0 days of control mice with IR treatment (p < 0.01) (Fig. 2g). This result suggests that a significant benefit to knockdown of G0S2 and radiation over radiation alone.

To further determine the role of G0S2 in glioma response to IR, we stably overexpressed G0S2 in two glioma cell lines with low levels of endogenous G0S2 expression (Fig. 3a), LN229 and U87, and then treated U87/G0S2, U87/Control, LN229/G0S2, LN229/Control, U251/G0S2, and U251/Control with fractionated radiation. As shown in Fig. 3b, overexpression of G0S2 rendered resistance to IR in U87 and LN229 cells compared with the controls, respectively. Consistent with the results in vitro, in mice that received U87 cells, survival of control animals were significantly extended in mice with IR treatments, increasing median survival times from 35.5 to 54.0 days (p < 0.001). In contrast, IR treatments did not significantly enhance survival of G0S2-overexpressing glioma tumors (Fig. 3c). The effect of G0S2 overexpression on temozolomide (TMZ) sensitivity was also determined. As shown in Fig. 3d, G0S2-overexpression modestly enhanced TMZ resistance of U87 and U251 GBM cells only in the lower effective doses. This data suggests that G0S2 enhanced survival is greater for radiation responses compared to chemotherapy.

G0S2 regulates glioma cell DNA repair in response to IR
Emerging evidence suggests that activation of DNA repair is an important factor for glioma radiation resistance [4, 5]. We hypothesize that G0S2 also regulates glioma radiation response through activation of DNA repair. Since γ-H2AX foci have been widely used as a sensitive indicator for DNA repair [28, 29], we used immunofluorescence staining to test and quantify γ-H2AX foci-positive cells in response to IR in GSC 1123/shC, GSC 1123/shG0S2–1 and 1123/shG0S2–2 cells. As shown in Fig. 4a and b, after 8 h post-IR with 10 Gy, GSC 1123/shC cells showed γ-H2AX foci formation. Compared with the controls, knockdown of G0S2 in GSC 1123 cells significantly enhanced IR-induced γ-H2AX foci-formation (Fig. 4a and b). IR-induced up-regulation of γ-H2AX was further confirmed by western blotting assay (Fig. 4c). In contrast, compared with the controls, overexpression of G0S2 in glioma LN229 and U87 glioma cells significantly prevented IR-induced
γ-H2AX foci formation in these cells (Fig. 4da n de). Additionally, overexpression of G0S2 also inhibited IR-induced γ-H2AX expression (Fig. 4f). This data suggests that G0S2 involves glioma response to IR treatment through regulating DNA repair pathways.

**G0S2 promotes 53BP1 stability in glioma cells in response to IR**

Accumulated evidence has established critical roles for the tumorsuppressor 53BP1 (53BP1) in non-homologous end-joining (NHEJ) double-strand break (DSB) DNA repair [30–32], and Rad51 in homologous recombination (HR) DSB DNA repair [33]. In addition, 53BP1 and Rad51 are important for glioma tumorigenesis [6, 34]. Based on our results above, we hypothesized that G0S2 enhances radiation resistance of gliomas through regulation of Rad51 or 53BP1. As shown in Fig. 5a, LN229/Control and LN229/G0S2 cells without IR treatment showed basal levels of γ-H2AX, Rad51 and 53BP1 protein expression. At 2 h and 8 h post-IR, protein levels of 53BP1 and Rad51 were significantly reduced in LN229/G0S2 cells compared to LN229/Control cells. In contrast, G0S2 knockdown by shG0S2, G0S2-1, and G0S2-2 significantly increased the levels of 53BP1 and Rad51, indicating that G0S2 enhances the stability of 53BP1 and Rad51 in response to IR treatment.
γ-H2AX, Rad51 and 53BP1 were elevated in both cell lines. Compared with LN229/Control cells, the levels of γ-H2AX protein were significantly lower in LN229/G0S2 cells at 2 h and 8 h post-IR whereas the levels of 53BP1 protein were markedly higher (Fig. 5a). The levels of Rad51 protein did not show any differences in LN229/G0S2 cells compared with LN229/Control cells at 2 h and 8 h post-IR treatments, respectively (Fig. 5a). Immunofluorescent staining also indicated that the ratio of 53BP1 foci positive cells were higher in LN229/G0S2 cells compared with LN229/Control cells at 8 h post-IR (Fig. 5b and c). We also determined cell apoptosis in these isogenic LN229 cells in response to IR. As shown in Fig. 5a, levels of cleaved PARP, a marker of cell apoptosis [35] were markedly increased in response to IR. However, levels of cleaved PARP were not affected by overexpression of G0S2 compared with the controls. Lastly, we assessed the expression of 53BP1 mRNA in LN229/G0S2 cells compared with in LN229/Control cells in response to IR. However, we did not find appreciable changes of the levels of 53BP1 mRNA in these isogenic cells (Additional file 2: Figure S2), suggesting that alterations are regulated at the post-translational level. In sum, these results show that 53BP1 protein expression is regulated by G0S2 in glioma cell responses to IR treatment.

Since 53BP1 stability is regulated by ubiquitination in DNA repair [36, 37], we tested if G0S2 regulates 53BP1 ubiquitination and stability in glioma cells in response to IR. As shown in Fig. 5d, comparing untreated with irradiated glioma cells, 53BP1 ubiquitination was significantly enhanced by IR in control U87 and LN229 cells at 8-h post-IR. However, G0S2 overexpression inhibited IR-stimulated 53BP1 ubiquitination compared with the controls. We subsequently assessed the protein stability of 53BP1 in the presence of cycloheximide (CHX) that blocks de novo protein synthesis with or without G0S2 overexpression in response to IR. As shown in Fig. 5e and f, overexpression of G0S2 markedly inhibited 53BP1 protein degradation compared with the control. Moreover, the treatment with MG132, a proteasome inhibitor, significantly delayed 53BP1 degradation in G0S2-overexpressed cells. This data supports the notion that G0S2 regulates ubiquitination and proteasome-dependent degradation of 53BP1 in gliomas in response to IR.

To further demonstrate that G0S2 regulates glioma radioresistance through 53BP1, we knocked down 53BP1 using shRNAs in U87/G0S2 and LN229/G0S2 cells and determined γ-H2AX expression and γ-H2AX foci formation in response to IR. As shown in Fig. 5g, knockdown of 53BP1...
with two different shRNAs, sh53BP1–1 and sh53BP1–2, increased γ-H2AX protein levels in U87/G0S2 and LN229/G0S2 cells compared with the controls in response to IR. Depletion of 53BP1 markedly attenuated γ-H2AX foci cell formation in U87/G0S2 and LN229/G0S2 cells compared with the controls (Fig. 5h and i). Moreover, knockdown of 53BP1 enhanced U87/G0S2 cell radiosensitivity compared with the control (Fig. 5j), and significantly extended animal survival with median survival times of 38.5 days compared to 32.5 days of control animals (Fig. 5k). Taken together, these data support that G0S2 regulates glioma radioresistance through mediating 53BP1 stability in response to IR.

G0S2 activates mTOR-S6K signaling and thereby inhibits RNF168 expression and RNF168-mediated 53BP1 ubiquitination in response to IR

E3 ubiquitin ligase RNF168 mediates 53BP1 stability and sensitivity of cancer cells to DNA damaging agents and irradiation [37, 38], and RNF168 expression is inhibited by rapamycin (mTOR)-ribosomal S6 kinase (S6K)
Fig. 5 G0S2 promotes 53BP1 stability in glioma cells in response to radiation. a WB analyses of effect of G0S2 overexpression on γ-H2AX, Rad51, 53BP1 and PARP expression in response to IR. Arrow, cleaved PARP. b Representative images of 53BP1 staining of glioma LN229 cells with or without overexpression of G0S2 at 8 h post-IR with 10 Gy. Scale bars: 50 μm. c Quantitative 53BP1 staining of B. Error bars, SD. *, p < 0.05. d G0S2 increased 53BP1 ubiquitination in response to IR. His-Ub was transiently transfected into glioma U87 and LN229 cells with or without overexpression of G0S2. Proteins were pulled down with Ni-NTA beads. 53BP1(Ub)n, polyubiquitinated 53BP1. e The half-life of 53BP1 in LN229 cells with overexpression of G0S2 was prolonged compared with the control. After 8-h post-IR, cells were treated with CHX (10 μg/ml) for indicated times with or without the proteasome inhibitor MG132 (10 μM). f Quantitative 53BP1 protein levels of panel e using image software. Error bars, SD. *, p < 0.05. g Depletion of 53BP1 with two different shRNAs (sh53BP1–1 and sh53BP1–2) increased G0S2-attenuated γ-H2AX expression in response to radiation in glioma LN229 and U87 cells. h Representative images of γ-H2AX staining of g. Scale bars: 50 μm. i Quantitative γ-H2AX staining of h. Error bars, SD. *, p < 0.05. j Clonogenic survival assay of U87/G0S2 cells transduced with control shRNA (shC) or 53BP1 shRNAs (sh53BP1–1 and sh53BP1–2). Colonies formed by surviving cells 26 days after IR are shown. Error bars, SD. *, p < 0.05. k Survival curves for mice implanted with 5 × 10^5 cells of U87/G0S2/shC or U87/G0S2/sh53BP1–1 and left untreated or given daily closed 2.5 Gy IR from day 14 to 17 after cell implantation. Arrows, IR treatment times. Data represent two independent experiments with 6 mice per group with similar results.
in radioresistant GSCs. Knockdown of G0S2 by responses of gliomas. Expression level of G0S2 was upregulated in radioresistant GSCs and elevated in clinical resistance in GBM linked to upregulation of G0S2. G0S2 is related with G0S2-mediated lipid droplet stability.

Discussion

In this study, we described a novel mechanism of radiation resistance in GBM linked to upregulation of G0S2. G0S2 is upregulated in radioresistant GSCs and elevated in clinical GBM biopsies. Modulation of G0S2 expression affects GBM responses to IR treatments in vitro and in vivo through mTOR/S6K/RNF168/53BP1-regulated DNA repair, suggesting G0S2 as a potential mediator of glioma responses to IR. Moreover, G0S2-induced radiosensitivity is related with G0S2-mediated lipid droplet stability.

Our data demonstrate for the first time that G0S2 functions as a mediator of radiation resistance in gliomas. G0S2 is a 12 kDa small protein that was initially shown to be involved in cell cycle progression [7, 8]. G0S2 was then characterized as an inhibitor of adipose triglyceride lipase (ATGL) to regulate lipolysis [12]. Recently, G0S2 was described as a positive regulator of hypoxia-induced ATP production [9]. G0S2 was rapidly and transiently induced by hypoxia, and physiological enhancement of G0S2 expression prevented cells from ATP depletion and induced a cellular tolerance for hypoxia stress [9]. G0S2 also was identified as a NF-κB-dependent downstream factor of TNF-α in primary foreskin fibroblasts [10]. PN-MES transition of GSCs promoted radiosensitivity in a TNF-α/NF-κB-dependent manner [40]. Here, we show that G0S2 modulates radiation responses of gliomas. Expression level of G0S2 was upregulated in radioresistant GSCs. Knockdown of G0S2 by shRNAs sensitized glioma cells to IR treatments in vitro and glioma tumorigenicity. In contrast, overexpression of G0S2 increased the resistance of glioma cell and tumor to IR treatments, demonstrating an undescribed function of G0S2 in glioma radiosistance.

Our results suggest that G0S2 mediates glioma radiosensitivity through 53BP1-regulated DNA repair. Accumulated data demonstrate that 53BP1 is critical in radiation response of tumors [36, 37], including glioma [6]. Depletion of endogenous 53BP1 sensitized glioma cells to IR treatment in vitro and in vivo [6]. Moreover, 53BP1 stability was shown to be regulated by ubiquitination in response to irradiation [31, 37]. Here, our results support this notion and show that G0S2 overexpression inhibited 53BP1 ubiquitination and upregulated 53BP1 foci cell formation in glioma cells, and thereby reduced γ-H2AX expression and γ-H2AX foci cell formation in response to irradiation. Consistent with this, depletion of 53BP1 inhibited G0S2 overexpression-induced radiosensitivity.

Our results also suggest that G0S2 mediates 53BP1 ubiquitination and stability through mTOR/S6K signaling-regulated RNF168 expression. 53BP1 stability is regulated by E3 ubiquitin ligase RNF168 in DNA damage [37, 38]. mTOR-S6K phosphorylates RNF168 at Ser60 and thereby inhibits its E3 ligase activity, accelerates its proteolysis, and impairs its function in DNA damage response [38]. Additionally, mTOR-S6K signaling is activated by exogenously supplied oleic acid (OA), a monounsaturated omega-9 fatty acid [39]. In this study, we show that lipolytic inhibitor G0S2 reduces lipid droplet turnover and thereby activates mTOR-S6K signaling, inhibits E3 ligase RNF168 expression and RNF168-mediated 53BP1 protein ubiquitination in response to IR. Thus, our data suggest that G0S2 regulates 53BP1 stability and DNA repair through mTOR-S6K signaling-mediated RNF168.

Previous studies have shown G0S2 to be both onco-genic and tumor suppressive. G0S2 was found epigenetically silenced in lung cancer and breast cancer lines [10], and engineered expression of G0S2 induced cell apoptosis through G0S2 binding to and antagonizing Bcl-2 in a lung and a colon cancer cell line [10] but not in breast cancer cell lines [41]. In a chronic myeloid leukemia cell line, K562, G0S2 gene was found to be silenced by gene methylation, and upregulation of G0S2 expression by retroviral transduction or treatment with 5-azacytidine inhibited the proliferation of K562 cells both in vitro and in a xenograft model [42]. Although Zagani et al. [43] demonstrated that Eμ-Myc transgenic mouse model was not the correct model to conduct studies on G0S2, they found deletion of the G0S2 gene in mice did not show any effect on the latency of cancer progression in the Eμ-Myc model of lymphoma [43]. By analyzing The Cancer Genome Atlas (TCGA), Fukunaga et al. showed that pateints in the higher signaling [38]. Moreover, exogenously supplied oleic acid (OA) activates mTOR-S6K signaling [39]. We hypothesized that G0S2 reduces lipid droplet turnover and thereby activates the mechanistic target of rapamycin (mTOR)-ribosomal S6 kinase (S6K) signaling, reduces E3 ligase RNF168 expression, inhibits RNF168-mediated protein ubiquitination of 53BP1, and increases 53BP1 stability in response to IR. To assess this, we detected effects of G0S2 overexpression on S6K phosphorylation (p-S6K) and RNF168 protein expression in U87 and LN229 cells. As shown in Fig. 6a, overexpression of G0S2 significantly increased p-S6K levels and decreased RNF168 protein expression. We then transiently transfected RNF168 into U87/G0S2 and LN229/G0S2 cells, and found that ectopic expression of RNF168 inhibited 53BP1 expression (Fig. 6b) and 53BP foci cell formation (Fig. 6c and d) upregulated by G0S2 overexpression in indicated glioma cells compared to the controls at 8 h post IR, whereas it increased γ-H2AX expression (Fig. 6b) and γ-H2AX foci cell formation inhibited by G0S2 overexpression (Fig. 6c and e). We further found that overexpression of RNF168 enhanced 53BP1 ubiquitination inhibited by G0S2 overexpression in U87 and LN229 cells in response to IR (Fig. 6f). Our results demonstrate that G0S2 regulates glioma radiosensitivity through mTOR/S6K/RNF168/53BP1-regulated DNA repair.

Our data demonstrate that G0S2 reduces lipid droplet turnover and thereby activates the mechanistic target of rapamycin (mTOR)-ribosomal S6 kinase (S6K) signaling, reduces E3 ligase RNF168 expression, inhibits RNF168-mediated protein ubiquitination of 53BP1, and increases 53BP1 stability in response to IR. Moreover, G0S2-induced radiosensitivity is related with G0S2-mediated lipid droplet stability.

Our results also suggest that G0S2 mediates 53BP1 ubiquitination and stability through mTOR/S6K signaling-regulated RNF168 expression. 53BP1 stability is regulated by E3 ubiquitin ligase RNF168 in DNA damage [37, 38]. mTOR-S6K phosphorylates RNF168 at Ser60 and thereby inhibits its E3 ligase activity, accelerates its proteolysis, and impairs its function in DNA damage response [38]. Additionally, mTOR-S6K signaling is activated by exogenously supplied oleic acid (OA), a monounsaturated omega-9 fatty acid [39]. In this study, we show that lipolytic inhibitor G0S2 reduces lipid droplet turnover and thereby activates mTOR-S6K signaling, inhibits E3 ligase RNF168 expression and RNF168-mediated 53BP1 protein ubiquitination in response to IR. Thus, our data suggest that G0S2 regulates 53BP1 stability and DNA repair through mTOR-S6K signaling-mediated RNF168.
G0S2 expression group had a poorer prognosis [18]. They also demonstrated that G0S2 expression levels were higher in recurrent tumor specimens that at the initial diagnosis in the same patients [18]. Here in this study, we show that G0S2 promotes tumor growth in gliomas. Compared with paired normal brain tissues, we further found that the level of G0S2 expression was elevated in clinical tumor specimens. Patients with high level of G0S2 expression in GBM have a poorer prognosis compared with those with low level of G0S2 expression. Our analysis of GSE7969 and GDS1962 datasets supports this observation demonstrating that G0S2 expression was increased in GBM tumors compared with normal brain tissues. By using genetic approaches targeting G0S2, we found that shRNA knockdown of G0S2 inhibited glioma tumorigenesis in vivo. Conversely, overexpression of G0S2 promoted tumor growth in orthotopic glioma models. The differences between our results and some of earlier studies of G0S2 in other cancers could reflect context-dependent mechanisms of action in different type of cancers.

That G0S2 functions as an oncogene or tumor suppressor may be related with G0S2 lipolytic inhibitor activity. G0S2 suppressed mouse embryonic fibroblasts (MEF) oncogenic transformation induced by overexpression of
HRAS or EGFR, which was independent of G0S2 lipolytic inhibitor function [41]. Lipid droplets were shown to be inversely correlated with GBM patient survival [14]. Depletion of SOAT1, an inhibitor of lipid droplet formation, suppressed GBM growth [14]. In this study, we demonstrate that G0S2-induced radioresistance is related with G0S2-regulated lipid droplet stability in gliomas. Knockdown of G0S2 promoted lipid droplet turnover, cell apoptosis, inhibited radioresistance in GSCs, and extended xenograft tumor animal survival. Consistent with this, oleic acid treatment promoted lipid droplet formation and reduced G0S2 shRNA-inhibited cell apoptosis induced by IR. The molecular insight of relation between lipid droplet turnover and tumorigenicity warrants further investigation.

Conclusions
In summary, our results demonstrate a previously unknown function of G0S2 in enhancing glioma radioresistance through regulation of 53BP1 protein stability, which is related with G0S2 lipolytic inhibitor function. The newly elucidated roles of G0S2 in glioma radioresistance also provide a strong rationale for targeting this molecule in clinical treatment of human gliomas.

Additional files

**Additional file 1: Figure S1.** Establish radioresistant glioma stem cells. A. Experiment protocol for establishment of radioresistant GSCs. B. Flow cytometric analysis for GSC 1123-C and GSC 1123-R cells stained with annexin V and propidium iodide at indicated time points after exposure to 6 Gy of ionization radiation or not. C. Quantification of apoptotic cells from B. Error bars SD., *p < 0.05. D. Representative images of clonogenic survival assay of GSC 1123-C and GSC 1123-R cells. Colonies formed by surviving cells 15 days after IR are shown. Scale bars: 1 mm. E. Quantification of colonies in D. Error bars, SD., *p < 0.05. (EPS 6598 kb)

**Additional file 2: Figure S2.** Quantitative real-time-PCR (QRT-PCR) analysis of 53BP1 mRNA expression in LN229/G0S2 and LN229/Control cells after IR treatment. ACTB was used as an internal control. Errors bars, SD., *p < 0.05. (EPS 837 kb)

Abbreviations
ALDH1A3: Aldehyde dehydrogenase 1A3; G0S2: G0/G1 switch gene 2; GBM: Glioblastoma; GSC: Glioma stem-like cell; IR: Ionizing radiation; MES: Mesenchymal; mTOR: mammalian target of rapamycin; NSC: Neural stem cell; OA: Oleic acid; PN: Proneural; S6K: Ribosomal S6 kinase

Acknowledgements
We thank Ichiro Nakano for providing patient-derived glioma stem cells.

Funding
This work was supported in part by National Natural Science Foundation of China (81572467, 81774078 to H. Feng; 81401055, 81772653 to Y. Li; 81502142 to Y. Wang; 81260371 to K. Yang); the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (No. 2014024); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (No. 20161310), New Hundred Talent Program (Outstanding Academic Leaders) at Shanghai Municipal Health Bureau (2017R021), and the State Key Laboratory of Oncogenes and Related Genes in China (No. 91–17-25) to H. Feng.

Availability of data and materials
All relevant data and materials are available from the authors. RNA-Seq data reported in this study have been deposited with the Gene Expression Omnibus under the accession GEO ID: GSE79772. All the other data supporting the finding of this study are available within the article and its Supplementary Information files or from the corresponding author on reasonable request.

Authors’ contributions
This study was conceived by HF; HF, YL, and KY designed the study; YY, YH, and WZ performed the experiments; HF, YL, KY, and YW analyzed and interpreted the data; YY, AAA, YB, BH, SC, KY, and YL reviewed the manuscript; HF wrote the paper with comments from all authors.

Ethics approval and consent to participate
All the work related to human tissues were performed under the Institutional Review Board approved protocols approved at Shanghai Jiao Tong University, according to the Declaration of Helsinki, and the investigators obtained informed written consent from the subjects. All animal experiments were performed in accordance to a protocol approved by Shanghai Jiao Tong University Institutional Animal Care and Use Committee (IACUC).

Consent for publication
All authors agree to publish.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai Cancer Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China. 2Department of Radiotherapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China. 3Ken and Ruth Davee Department of Neurology, Lou & Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. 4Department of Neurosurgery, The First Affiliated Hospital of Hainan Medical University, Haikou 570102, Hainan, China. 5Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.

Received: 29 January 2019 Accepted: 21 March 2019
Published online: 05 April 2019

References
1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.
2. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–22.
3. Moding EJ, Kastan MB, Kirsch DG. Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov. 2013;12(7):526–42.
4. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756–60.
5. Brett-Morris A, Wright BM, Seo Y, Pasupuleti V, Zhang J, Lu J, et al. The polyamine catabolic enzyme SAT1 modulates tumorigenesis and radiation response in GBM. Cancer Res. 2014;74(23):6925–34.
6. Squatrito M, Vanoli F, Schultz N, Jasin M, Holland EC. 53BP1 is a haploinsufficient tumor suppressor and protects cells from radiation response in glioma. Cancer Res. 2012;72(20):5250–60.
7. Russell L, Forsdyke DR. A human putative lymphocyte G0/G1 switch gene containing a CpG-rich island encodes a small basic protein with the potential to be phosphorylated. DNA Cell Biol. 1991;10(8):S81–91.
8. Sidekowsky DP, Blum S, Forsdyke RE, Forsdyke DR. A set of human putative lymphocyte GØ/G1 switch genes includes genes homologous to rodent cytokine and zinc finger protein-encoding genes. DNA Cell Biol. 1990;8(8):579–87.

9. Kikora H, Kato H, Fujikawa M, Tsukamoto O, Suzuki T, Imanura H, et al. Evaluation of intramitochondrial ATP levels identifies GØ/G1 switch gene 2 as a positive regulator of oxidative phosphorylation. Proc Natl Acad Sci U S A. 2014;111(13):273–8.

10. Welch C, Santra MK, El-Assaad W, Zhu X, Huber WE, Keys RA, et al. Identification of a protein, GØS2, that lacks Bcl-2 homology domains and interacts with and antagonizes Bcl-2. Cancer Res. 2009;69(17):6782–9.

11. Zanndbergen F, Mandard S, Escher P, Tan NS, Patsouris D, Jatkoe T, et al. The GØ/G1 switch gene 2 is a novel PPAR target gene. Biochem. J. 2005;392(Pt 2):213–24.

12. Yang X, Lu X, Lombs M, Rha GB, Chi YI, Guerin TM, et al. The GØ/G1 switch gene 2 regulates adipose lipoysis through association with adipose triglyceride lipase. Cell Metab. 2010;11(3):194–205.

13. Yamada T, Park CS, Burns A, Nakada D, Lacorazza HD. The cytosolic molecule inhibitor attenuates the growth of cancer cells. Oncotarget. 2015;6(36):44260–70.

14. Geng F, Cheng X, Wu K, Yao JY, Cheng C, Guo JY, et al. Inhibition of SOAT1 regulates DSB repair using Rif1 to control 53BP1 instability. Neuro-Oncology. 2011;13(12):1277–87.

15. Zagani R, Lazaro-Trueba J, Kerr P, Lord CJ, Dexter T, Iravani M, et al. p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep. 2006;7(2):219–24.

16. Westermark UP, Lindberg N, Roswall P, Bräström D, Helgadottir HR, Hedre SM, et al. RAD51 can inhibit PDBG-B-induced gliomagenesis and genomic instability. Neuro-Oncology. 2011;13(12):1277–87.

17. Bouloures AH, Yakoğlu AV, Ivanova V, Stoica BA, Wang G, Iyer SR, et al. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem. 1999;274(33):22992–3004.

18. Han X, Zhang J, Chung J, Mayca Pozo F, Tran A, Seachrist DD, et al. UbCh7 regulates S3BP1 stability and DSB repair. Proc Natl Acad Sci U S A. 2014;111(49):17466–61.

19. Hu Y, Wang C, Huang K, Xia F, Parvin JD, Mondal N. Regulation of S3BP1 protein stability by RNfB and RNfB168 is important for efficient DNA double-strand break repair. PLoS One. 2014;9(10):e110522.

20. Xie X, Hu H, Tong X, Li L, Liu X, Chen M, et al. The mTOR-S6K pathway links growth signalling to DNA damage response by targeting RNfB168. Nat Cell Biol. 2014;16(3):230–31.

21. Menon D, Salloum D, Bernfeld E, Gorodetskii A, Akselrod IA, Frias MA, et al. Lipid sensing by mTOR complexes via de novo synthesis of phosphatic acid. J Biol Chem. 2017;292(15):6303–11.

22. Bhattacharjan K, Vainall S, Ehlilasaran R, Hoffmann A, Hollingworth F, et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell. 2013;24(3):331–46.

23. Yim CY, Sekula DJ, Hever-Jardine MP, Liu X, Warzecha JM, Tam J, et al. DNA demethylation of the G0S2 gene on the transcription of G0S2 in squamous lung cancer cell lines with or without nuclear receptor agonists. Biochem Biophys Res Commun. 2009;380(1):283–7.

24. Fukunaga T, Fujita Y, Kishima H, Yamashita T. Methylation dependent down-regulation of G0S2 as a gene frequently methylated in squamous lung cancer. J Clin Invest. 2010;120(8):895–902.

25. Kusakabe M, Kutomi T, Watanabe K, Emoto N, Aki N, Kage H, et al. Identification of G0S2 as a gene frequently methylated in squamous lung cancer by combination of in silico and experimental approaches. Int J Cancer. 2010;126(8):1895–902.

26. Kusakabe M, Watanabe K, Emoto N, Aki N, Kage H, Nakase T, et al. Impact of DNA methylation of the G0S2 gene on the transcription of G0S2 in squamous lung cancer cell lines with or without nuclear receptor agonists. Biochem Biophys Res Commun. 2009;380(1):283–7.

27. Mao P, Joshi K, Li J, Kim SH, Li P, Santana-Santos L, et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci U S A. 2013;110(21):8644–9.

28. Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, et al. EGFR suppresses glioblastoma growth via blocking SREBP-1-mediated lipogenesis. Cancer Lett. 2012;310(2):178–85.

29. Willers H, Gheorgiu L, Liu Q, Selfsthun JA, Wirth LJ, Krause M, et al. Damage response assessments in human tumor samples provide functional biomarkers of Radiosensitivity. Semin Radiat Oncol. 2015;25(4):237–50.

30. Zimmermann M, Lottersberger F, Buonomo SB, Steir A, de Lange T. S3BP1 regulates DSB repair using Rif1 to control end resection. Science. 2013;339(6120):700–4.